- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.09. | William Blair initiates Obsidian Therapeutics stock with outperform rating | 2 | Investing.com | ||
| 28.08. | Obsidian Therapeutics, Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 05.08. | Obsidian Therapeutics Completes Galera Merger And $350 Million Private Placement | 1 | pulse2.com | ||
| OBSIDIAN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 05.08. | Piper Sandler initiates Obsidian Therapeutics stock with overweight | 2 | Investing.com | ||
| 05.08. | Piper Sandler startet Coverage für Obsidian Therapeutics Aktie mit "Overweight" | 1 | Investing.com Deutsch | ||
| 05.08. | RTW Biotech Opp. - Obsidian Therapeutics merges with Galera | 2 | RNS | ||
| 04.08. | Galera Therapeutics, Inc. - 15-12G, Securities registration termination | 1 | SEC Filings | ||
| 03.08. | Obsidian Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 03.08. | Obsidian Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 03.08. | Obsidian Therapeutics Completes Galera Therapeutics Merger with $350M Private Placement Financing | 2 | Contract Pharma | ||
| 03.08. | Obsidian Therapeutics completes merger with Galera | 1 | Investing.com | ||
| 03.08. | Obsidian Therapeutics Completes Closing of Transaction with Galera Therapeutics and Previously Announced Private Placement of $350 Million | 556 | Business Wire | • Obsidian Therapeutics to focus on the advancement of its pipeline of novel engineered TIL cell therapies for the treatment of patients with solid tumors
• Post-transaction cash and cash equivalents... ► Artikel lesen | |
| 31.07. | Galera Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.07. | Galera Therapeutics, Inc. - 8-K, Current Report | 11 | SEC Filings | ||
| 15.05. | Galera Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 14.05. | Galera Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 19.04. | Obsidian Therapeutics, Galera Therapeutics Merger Comes With $350M Infusion for Cancer Drug Trials | 3 | MedCity News | ||
| 15.04. | Obsidian Therapeutics, Galera Therapeutics to advance cell therapy following reverse merger | 4 | BioPharma Dive | ||
| 15.04. | Obsidian Therapeutics To Merge With Galera Therapeutics In Reverse Merger | - | RTTNews | ||
| 15.04. | Obsidian Therapeutics to go public via Galera Therapeutics merger | 2 | Investing.com |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CRISPR THERAPEUTICS | 49,155 | -0,17 % | CRISPR Therapeutics auf Morgan Stanley Konferenz: Pipeline-Erweiterung und kommerzielle Fortschritte | ||
| NOVOCURE | 14,635 | +0,76 % | Novocure auf Morgan Stanley Konferenz: Strategie für Wachstum, Disziplin und Expansion | ||
| SPERO THERAPEUTICS | 0,994 | +1,43 % | H.C. Wainwright raises Spero Therapeutics price target to $6 | ||
| PRECISION BIOSCIENCES | 5,900 | +1,72 % | Precision BioSciences stellt auf H.C. Wainwright Konferenz Zwei-Säulen-Strategie vor | ||
| BOLT BIOTHERAPEUTICS | 3,600 | +1,12 % | Bolt Biotherapeutics, Inc.: Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected to be released with Bolt's 3Q 2026 resultsCash balance of $18.1 million as of... ► Artikel lesen | |
| HEMAB THERAPEUTICS | 41,190 | 0,00 % | Gubra A/S: Gubra collaboration partner Hemab announces first participant dosed in Phase 1 clinical trial of HMB-003, an investigational therapy for the management of heavy menstrual bleeding | Today, Gubra announced that its partner Hemab Therapeutics has dosed the first healthy volunteer in its Phase 1 clinical trial evaluating HMB-003, an investigational therapy for the management of heavy... ► Artikel lesen | |
| SCRIBE THERAPEUTICS | 33,000 | 0,00 % | Biotech Stocks At 52-Week Highs - Scribe Therapeutics Continues Rise After Nasdaq Debut, Royalty Pharma, Haemonetics, 10x Genomics, Labcorp Holdings | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 20, 2026, driven by key catalysts such as new product launches and the prospective release of data from clinical... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 45,320 | 0,00 % | Biotech Options Buzz: UTHR, NMRA, EWTX | ||
| DYNE THERAPEUTICS | 17,110 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| SHATTUCK LABS | 6,010 | 0,00 % | Shattuck Labs, Inc.: Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights | - Phase 1 clinical trial results for SL-325 demonstrated a favorable safety profile, a potentially best-in-mechanism immunogenicity profile, and durable DR3 blockade of TL1A binding, potentially enabling... ► Artikel lesen | |
| ABSCI | 9,650 | 0,00 % | Absci auf Morgan Stanley Healthcare-Konferenz: KI-Plattform im klinischen Test | ||
| MBX BIOSCIENCES | 62,91 | 0,00 % | MBX Biosciences, Inc.: MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism | Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail results and durable one-year clinical benefit Global registrational trial to enroll approximately 160 adults with HP to support... ► Artikel lesen | |
| TYRA BIOSCIENCES | 25,730 | 0,00 % | Tyra Biosciences (TYRA) Dabogratinib Delivers 57% Complete Response Rate in Phase 2 Trial. Is Phase 3 Supported? | ||
| QIAGEN | 38,410 | -0,51 % | AKTIE IM FOKUS: Qiagen ziehen an - Magazinbericht schürt Übernahmefantasie | FRANKFURT (dpa-AFX) - Bei den Aktien von Qiagen hat am Donnerstag ein Magazinbericht die bereits bestehende Übernahmefantasie angeheizt. Die Aktien des Molekulardiagnostik-Unternehmens zogen am Mittag... ► Artikel lesen | |
| ELECTRA THERAPEUTICS | 13,500 | +1,89 % | Electra Therapeutics, Inc.: Electra Therapeutics Announces Pricing of Upsized $350.0 Million Initial Public Offering | SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Electra Therapeutics, Inc., a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines... ► Artikel lesen |
OBSIDIAN THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 17,740 Euro und damit -0,06 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OBSIDIAN THERAPEUTICS INC finden Sie auf Wallstreet Online.